Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217971 · ClinicalTrials.gov registry record · Phase 2
Dronabinol Treatment for Marijuana Addiction
A Phase 2 study of Marijuana Abuse, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 1
- Study location
NCT00217971: Completed Phase 2 study of Marijuana Abuse, sponsored by New York State Psychiatric Institute.
NCT00217971 is a Phase 2 study of Marijuana Abuse that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 156 participants, above the 60-participant average among 4 other Marijuana Abuse trials with a reported enrollment target (160% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00217971, a Phase 2 study of Marijuana Abuse, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal.
Primary Outcome
Timeline Followback self report data was collected. This daily report was used to assess the proportion of patients abstinent during weeks 7 and 8 of the clinical trial.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dronabinol
Study Locations (1)
New York
- Research Foundation for Mental Hygiene, Inc. - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2005-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
What the finished NCT00217971 record still lists
NCT00217971 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 4 other Marijuana Abuse trials with a reported enrollment target (160% higher).
The record links to 1 condition, with Marijuana Abuse appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00217971 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00217971 about?
NCT00217971 is a clinical study titled "Dronabinol Treatment for Marijuana Addiction". The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal.
What is the current status of trial NCT00217971?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2005-03. Estimated completion is 2009-12.
What conditions does trial NCT00217971 study?
This clinical trial studies the following conditions: Marijuana Abuse.
What interventions are being tested in trial NCT00217971?
The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG).
Who is sponsoring clinical trial NCT00217971?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00217971 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marijuana Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
COMPLETED · Phase 2
-
Therapeutic Substance Abuse Treatment in Pregnancy - 1
COMPLETED · Phase 2
-
Effects of Cannabidiol on Marijuana-seeking in Humans
COMPLETED
-
Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia